Navigation Links
Cardinal Health, GE Healthcare Broaden Relationship to Offer Greater Access to Myoview(TM) Imaging Agent
Date:3/18/2008

DUBLIN, Ohio, and WAUWATOSA, Wis., March 18 /PRNewswire-FirstCall/ -- Cardinal Health and GE Healthcare announced an agreement today to broaden the availability of GE Healthcare's Myoview(TM) (Tetrofosmin) cardiac imaging agent through Cardinal Health's leading network of specialized nuclear pharmacies.

The agreement will give Cardinal Health's customers greater access to Myoview(TM), a leading myocardial perfusion imaging technetium agent used in the diagnosis and treatment of heart disease.

"With this agreement, Myoview will over time become the flagship branded cardiac imaging agent offered through Cardinal Health's nuclear pharmacies," said John Rademacher, president, Nuclear and Specialty Pharmacy Services for Cardinal Health. "Our commitment to the nuclear pharmacy business runs deep, and partnering with GE Healthcare to provide broader access to their product portfolio illustrates the unique way Cardinal Health can bring service and value to our customers and the nuclear medicine community."

Cardinal Health operates the largest radiopharmacy network in the United States with more than 150 nuclear pharmacy locations. It is also the largest employer of nuclear pharmacists in the world. The combination of that expertise and the size of its network allows Cardinal Health to reach 85 percent of all U.S. hospitals within three hours and provide service and clinical expertise to the nuclear medicine community.

"GE Healthcare and Cardinal Health are ideal collaborators to advance the field of nuclear medicine," said John Chiminski, president and CEO of Medical Diagnostics at GE Healthcare. "Myoview has been a strong and growing brand in the nuclear cardiac imaging market for more than a decade, and partnering to bring it to Cardinal Health's radiopharmacies will help clinicians reach even more patients."

"We are committed to continually investing in nuclear medicine," said Chiminski. "We believe working together with Cardinal Health will help us to do just that."

ABOUT CARDINAL HEALTH

Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is an $87 billion, global company serving the health care industry with products and services that help hospitals, physician offices and pharmacies reduce costs, improve safety, productivity and profitability, and deliver better care to patients. With a focus on making supply chains more efficient, reducing health care-associated infections and breaking the cycle of harmful medication errors, Cardinal Health develops market-leading technologies, including Alaris(R) IV pumps, Pyxis(R) automated dispensing systems, MedMined(TM) electronic infection surveillance service, VIASYS(R) respiratory care products and the CareFusion(TM) patient identification system. The company also manufactures medical and surgical products and is one of the largest distributors of pharmaceuticals and medical supplies worldwide. Ranked No. 19 on the Fortune 500, Cardinal Health employs more than 40,000 people on five continents. More information about the company may be found at http://www.cardinalhealth.com

ABOUT GE HEALTHCARE

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, performance improvement, drug discovery, and biopharmaceutical manufacturing technologies is helping clinicians around the world re-imagine new ways to predict, diagnose, inform, treat and monitor disease, so patients can live their lives to the fullest.

GE Healthcare's broad range of products and services enable healthcare providers to better diagnose and treat cancer, heart disease, neurological diseases and other conditions earlier. Our vision for the future is to enable a new "early health" model of care focused on earlier diagnosis, pre-symptomatic disease detection and disease prevention. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our website at http://www.gehealthcare.com.

ABOUT MYOVIEW, SELECT SAFETY INFORMATION

Myoview(TM) (technetium Tc-99m Tetrofosmin) In studying patients with known or suspected coronary artery disease, care should be taken to ensure continuous cardiac monitoring and the availability of emergency cardiac treatment. As with all injectable drug products, allergic reactions and anaphylaxis may occur. Pharmacologic induction of cardiovascular stress may be associated with serious adverse events such as myocardial infarction, arrhythmia, hypotension, bronchoconstriction, and cerebrovascular events. Caution should be used when pharmacologic stress is selected as an alternative to exercise; it should be used when indicated and in accordance with the pharmacologic stress agent's labeling. The most common adverse reactions reported from post-marketing experience with Myoview included rash, urticaria, abnormal vision, allergic reactions, and fever.

Before use of the product please refer to the product's full prescribing information, available at http://www.myoview.com/


'/>"/>
SOURCE GE Healthcare; Cardinal Health
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cardinal Health Reaffirms Fiscal 2008 EPS Guidance, Updates Segment Profit Outlook
2. Cardinal Health Names CEO R. Kerry Clark as Chairman; Company Founder Robert D. Walter to Retire After 36 Years
3. Cardinal Health To Announce First-Quarter Results on November 5
4. Cardinal Health Announces Sector Management Change
5. Cardinal Health Reports First Quarter Results
6. Cardinal Health, Sentry Data Systems Introduce New Technology to Help Health Care Providers More Cost-Efficiently Care for Underserved
7. Cardinal Health Receives DEA Order to Temporarily Cease Distribution of Controlled Substances from Auburn, Wash. Facility
8. Cardinal Health Foundation Grants $537,000 to Rural, Public Hospitals in Support of IHIS 5 Million Lives Campaign
9. Cardinal Health to Cease Distribution of Controlled Substances from Florida Facility
10. Cardinal Health to Announce Second-Quarter Results on January 29
11. Cardinal Health Taps Teva Executive George Barrett to Lead Healthcare Supply Chain Services Sector
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2016)... ... April 30, 2016 , ... ... RANKED Health , a program to critically evaluate and rank health-focused applications ... the program is to provide independent, unbiased and accurate information to help accelerate ...
(Date:4/30/2016)... ... April 30, 2016 , ... ... and CEO of EMED, today signed a multifaceted agreement which will allow for ... Northern Caribbean University Department of Natural and Applied Sciences, Allied Health and Nursing ...
(Date:4/30/2016)... ... , ... well is a challenge for all of us, but there are things we can do to ... “Research is showing more and more that there are simple, yet important steps that can ... age.” Top priorities Dr. Kohli’s recommends for her patients include;, , exercise ...
(Date:4/29/2016)... , ... April 30, 2016 , ... ... of patented products, announces the Pick Up Springboard, an automotive invention that improves ... Truck Manufacturing industry is worth $162 billion," says Scott Cooper, CEO and Creative ...
(Date:4/29/2016)... ... April 29, 2016 , ... In an article published April 16th ... for Botox and lip injections, which she underwent in order to feel more at ... and Arts Festival. The article explains that Ms. Mirmelli’s situation is not unique; many ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ( ... of oral drug delivery systems, announced today that the Company ... Joseph Gunnar & Co. LLC, taking place on ... Nadav Kidron , CEO of Oramed, will present a ...   PIONEERS 2016, presented by Joseph Gunnar ...
(Date:4/28/2016)... , April 28, 2016 ... development of innovative peptide and gene-based immunotherapeutics and vaccines for ... will be presenting at the 3rd Annual Growth Capital ... 5 th , 2016 at Caesars Palace in Las Vegas, Nevada.  ... am on Wednesday, May 4 th by Dr. ...
(Date:4/27/2016)... , Schweiz, April 27, 2016 ... Sachs CEO Forums in Zürich gab Strekin ... führenden Wirkstoffkandidaten STR001 zur Erhaltung des Resthörvermögens ... wurde, bekannt. Für die umfassende Phase-II-Doppelblindstudie mit ... Frankreich angeworben. STR001 wird während der Operation ...
Breaking Medicine Technology: